$146.93
0.24% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$146.93
+5.68 4.02% 1M
+18.75 14.63% 6M
+10.43 7.64% YTD
+10.40 7.62% 1Y
+26.62 22.13% 3Y
+49.26 50.44% 5Y
+93.68 175.92% 10Y
+82.68 128.68% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.35 0.24%

New AI Insights on Neurocrine Biosciences, Inc. Insights AI Insights on Neurocrine Biosciences, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$14.6b
Enterprise Value
$13.5b
Net debt
positive
Cash
$1.1b
Shares outstanding
99.7m
Valuation (TTM | estimate)
P/E
35.1 | 28.6
P/S
5.5 | 5.0
EV/Sales
5.1 | 4.6
EV/FCF
22.8
P/B
4.9
Financial Health
Equity Ratio
69.6%
Return on Equity
13.2%
ROCE
15.3%
ROIC
13.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.7b | $2.9b
EBITDA
$583.3m | $657.8m
EBIT
$553.6m | $674.2m
Net Income
$428.0m | $511.5m
Free Cash Flow
$593.1m
Growth (TTM | estimate)
Revenue
19.6% | 23.7%
EBITDA
-5.0% | 7.8%
EBIT
-5.9% | 15.6%
Net Income
10.9% | 49.9%
Free Cash Flow
34.8%
Margin (TTM | estimate)
Gross
98.4%
EBITDA
21.7% | 22.6%
EBIT
20.6%
Net
16.0% | 17.6%
Free Cash Flow
22.1%
More
EPS
$4.2
FCF per Share
$5.9
Short interest
5.3%
Employees
2k
Rev per Employee
$1.3m
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

31x Buy
89%
4x Hold
11%

Analyst Opinions

35 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,683 2,683
20% 20%
100%
- Direct Costs 44 44
32% 32%
2%
2,639 2,639
19% 19%
98%
- Selling and Administrative Expenses 1,142 1,142
22% 22%
43%
- Research and Development Expense 943 943
38% 38%
35%
583 583
5% 5%
22%
- Depreciation and Amortization 30 30
16% 16%
1%
EBIT (Operating Income) EBIT 554 554
6% 6%
21%
Net Profit 428 428
11% 11%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Negative
Reuters
3 days ago
Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.
Neutral
PRNewsWire
3 days ago
SAN DIEGO , Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not meet primary or key secondary endpoints. The primary objective of the study was to assess improvement in chore...
Neutral
Seeking Alpha
9 days ago
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today